Abbott (ABT) Q1 2026 earnings review
Exact Sciences Era Begins as MedTech Carries the Weight
Abbott delivered a highly transitional quarter. The company officially entered the fast-growing oncology diagnostics space by closing the Exact Sciences acquisition, while its core Medical Devices segment continued to print robust growth (+13.2% reported). However, the quarter was a tale of two trajectories: as MedTech soared, the Nutrition segment contracted sharply (-7.7% comparable) due to a strategic shift from price to volume. Adjusted EPS grew 6% to $1.15, masking underlying margin compression. Management updated FY26 EPS guidance to $5.38-$5.58, which absorbs $0.20 of Exact Sciences dilution but implies the core operational outlook remains intact.
🐂 Bull Case
The Exact Sciences acquisition adds over $3 billion in annual high-growth revenue, instantly establishing Abbott as a leader in cancer diagnostics (Cologuard, Cancerguard).
Medical Devices grew 8.5% on a comparable basis, led by Electrophysiology (+12.5%), Rhythm Management (+12.5%), and Diabetes Care (+7.4%). The portfolio is highly diversified and not reliant on a single product.
🐻 Bear Case
The self-inflicted strategy reset in Nutrition is painful. U.S. comparable sales collapsed 11.6% YoY. If the promised volume recovery in H2 fails to materialize, this segment will severely drag total company performance.
After a year of touting 100+ bps margin expansions, Q1 2026 Adjusted Gross Margin contracted by roughly 85 bps YoY to 56.3%. Tariffs and integration costs are starting to bite.
⚖️ Verdict: ⚪
Cautiously Bullish. The core growth engines (Devices and EPD) are executing flawlessly, and the Exact Sciences deal is a long-term winner. But the severe drop in Nutrition and reversing margin trends demand strict monitoring over the next two quarters.
Key Themes
Exact Sciences Integration: The Oncology Pivot
Abbott closed its acquisition of Exact Sciences on March 23, immediately booking $96 million in Cancer Diagnostics revenue in just 8 days. This is a massive strategic shift, adding Cologuard and the multi-cancer Cancerguard test to the portfolio. While it dilutes FY26 EPS by $0.20, it injects a highly durable, high-teens growth vertical into the Diagnostics segment.
Nutrition Strategy Reset Extracts a Heavy Toll
Reversing. As telegraphed by management in late 2025, the shift from price-led to volume-led growth is hurting. Worldwide comparable sales dropped 7.7%, but the real pain was in the U.S., which plummeted 11.6%. Management bet that trading price for volume will win long-term market share, but right now, investors are only seeing top-line destruction.
Medical Devices: Broad-Based Outperformance
Stable and strong. The MedTech division continues to carry the company. Diabetes Care (FreeStyle Libre) hit $2.08B in Q1, but the real stars were Electrophysiology (+16.7% reported) and Rhythm Management (+17.0% reported). The lack of reliance on a single sub-segment highlights the strength of Abbott's R&D engine.
Margin Expansion Reverses Course
Reversing. In 2025, Abbott consistently delivered ~100 basis points of gross and operating margin expansion. In Q1 2026, Adjusted Gross Margin fell to 56.3% (down from 57.1% in Q1 2025). This directly contradicts the prior positive narrative and is likely driven by the $200M+ in tariff impacts forecasted previously, combined with Exact Sciences integration costs.
Emerging Markets Power Established Pharma
Accelerating. The Established Pharmaceuticals Division (EPD) remains a quiet powerhouse, growing 9.0% on a comparable basis. The 'Key Emerging Markets' subsegment grew 9.4%, led by double-digit growth in Latin America and Asia. This geographic diversification provides excellent ballast against U.S. market volatility.
Amulet 360 and the Clinical Pipeline
Innovation remains front and center. The VERITAS study showed clinically meaningful closure rates for the investigational Amulet 360 LAA Occluder. Meanwhile, the FreeDM2 trial proved that FreeStyle Libre 3 outperforms fingersticks for Type 2 diabetics on basal insulin—a massive, underpenetrated TAM that is critical for Abbott's next phase of CGM growth.
Macro Pressures: Tariffs and FX
Despite a top-line beat, net foreign exchange was a headwind, and the previously warned 'few hundred million dollar' tariff impact is now explicitly flowing through the cost of goods sold. Management's global manufacturing footprint is mitigating the worst of it, but the friction is visible in the reversing gross margins.
Other KPIs
Reversing. Dropped roughly 85 basis points YoY from 57.1% in 25Q1. This breaks a multi-quarter streak of margin expansion and indicates that global tariffs and strategic pricing cuts in Nutrition are materially impacting profitability.
Accelerating. Grew 8.1% reported (3.3% comparable). Following a brutal 2025 where this unit was severely depressed by China Volume-Based Procurement (VBP) pricing cuts, it has officially stabilized and is returning to sequential growth.
Decelerating growth. Up 5.4% YoY compared to the 11% YoY growth seen in the same quarter last year. The bottom-line growth is slowing as top-line gains are offset by margin compression.
Guidance
Stable. Unchanged from prior expectations. This implies that management believes the Nutrition drop is isolated and temporary, and that the Exact Sciences addition (which is now in the comparable base) will support the high-single-digit target.
Decelerating slightly, but for a specific reason. This is a mechanical update to reflect $0.20 of dilution from the Exact Sciences acquisition. Adjusting for the M&A dilution, the core business implied guidance ($5.58 - $5.78) is largely in line with the $5.55-$5.80 outlook provided in late 2025.
Stable. The midpoint of $1.28 is practically flat against the $1.26 delivered in 25Q2. This highlights that Q2 will bear the brunt of the Exact Sciences integration dilution and the ongoing Nutrition turnaround.
Key Questions
Nutrition Volume Metrics
With U.S. Nutrition sales down nearly 12%, are you seeing any month-over-month stabilization in retail volumes following the Q4 pricing actions? When exactly in H2 do you expect to cross back into positive territory?
Exact Sciences Margin Drag
You've baked $0.20 of EPS dilution into FY26 for Exact Sciences. What is the exact timeline for this acquisition to become accretive to Adjusted EPS, and what are the primary synergy levers you plan to pull?
Gross Margin Trajectory
Adjusted Gross Margin contracted by roughly 85 basis points this quarter. How much of this was driven by tariffs versus Exact Sciences mix, and should we model further compression through the rest of the year?